Chemotherapy-induced peripheral neuropathy (CIPN) is a side effect of cancer treatment. Symptoms include pain, burning, tingling, constipation, muscle weakness, blood pressure changes and balance problems. Risk factors include longer duration of therapy, pre-existing neuropathy and type of chemotherapeutic agent.
Report Highlights
Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Chemotherapy Induced Peripheral Neuropathy-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy (Toxicology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide also reviews of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 7, 3, 1, 23, 4 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 3 and 1 molecules, respectively.
Find More Information@ http://www.reportsweb.com/chemotherapy-induced-peripheral-neuropathy-pipeline-review-h2-2017
Chemotherapy Induced Peripheral Neuropathy (Toxicology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
Get Sample Copy of Report@ http://www.reportsweb.com/inquiry&RW00011030782/sample
Companies Mentioned:
Achelios Therapeutics Inc
Advinus Therapeutics Ltd
Apollo Endosurgery Inc
Aptinyx Inc
Asahi Kasei Pharma Corp
Can-Fite BioPharma Ltd
Celgene Corp
Eisai Co Ltd
Immune Pharmaceuticals Inc
Insys Therapeutics Inc
Kineta Inc
KPI Therapeutics Inc
Krenitsky Pharmaceuticals Inc
Midatech Pharma US Inc
Mundipharma International Ltd
Nemus Bioscience Inc
Neurocentrx Pharma Ltd
Panacea Pharmaceuticals Inc
PeriphaGen Inc
PledPharma AB
Sova Pharmaceuticals Inc
Trevena Inc
WEX Pharmaceuticals Inc
Buy This Report@ http://www.reportsweb.com/buy&RW00011030782/buy/2000
List of Figures
Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Universities/Institutes, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017
Media Contact
Company Name: ReportsWeb
Contact Person: Rajat Sahni
Email: Send Email
Phone: +1-646-491-9876
Country: India
Website: http://www.reportsweb.com/chemotherapy-induced-peripheral-neuropathy-pipeline-review-h2-2017